(Date:5/15/2012)... AUSTIN, Texas, May 15, 2012 Vermillion, Inc. ... company, reported financial and operational results for the first ... Operational Highlights , In Q1, the volume ... help differentiate benign from malignant ovarian masses, was generally ... the quarter and demonstrated an increase of 28% to ...
(Date:5/15/2012)... 2012 Reportlinker.com announces that ... available in its catalogue: , ... and Market Forecast to 2019 ... Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment ... Summary GlobalData, the industry analysis ...
(Date:5/15/2012)... May 15, 2012 Generex Biotechnology Corporation (OTCBB: ... pivotal Phase III trials, is pleased to announce today ... of its wholly-owned subsidiary, Antigen Express, Inc., has been ... in clinical trial research and immuno-therapeutic treatments of breast ... Indiana University School of Medicine ...
(Date:5/15/2012)... BGI, one of the world,s ... GS FLX+ System has been successfully installed at its ... the existing array of short read sequencing technologies and ... GS FLX+ System, developed by 454 Life Sciences, a ... exceptional accuracy and high-throughput, making the system well suited ...
Breaking Biology Technology:Vermillion Reports First Quarter 2012 Results 2Vermillion Reports First Quarter 2012 Results 3Vermillion Reports First Quarter 2012 Results 4Vermillion Reports First Quarter 2012 Results 5Vermillion Reports First Quarter 2012 Results 6Vermillion Reports First Quarter 2012 Results 7Vermillion Reports First Quarter 2012 Results 8Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 3Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 4Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 5Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 6Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 7Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 8Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 9Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 10Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 2Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 3Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 4BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 2BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 3... April 30 Tigris Pharmaceuticals, Inc., a privately held ... on its novel molecule, AFP-464, during the recent AACR ... represents a significant advancement in the treatment of Triple ... of invasive breast cancer," stated Edmundo Muniz, M.D., Ph.D., ...
... Educational Webinar "How Organizations Can Make the Transition to ... Virtify, Inc. , , CAMBRIDGE, Mass., April ... the market leader in Enterprise Content Compliance solutions for ... ), a provider of Enterprise Compliance and Quality Management ...
... 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... for the first quarter ended March 31, 2009. , ... first quarter in what has been a difficult business ... and CEO of Angiotech. "Sales in our proprietary Surgical ...
Other Biology Technology:Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 2Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 3Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 4Event Alert: 'SPL R4 Compliance and its Impact on Regulatory Submission Processes' 2Event Alert: 'SPL R4 Compliance and its Impact on Regulatory Submission Processes' 3Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 21...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Biology Products:Biology NavigationMedical Navigation